Structure Therapeutics (GPCR) Cash from Operations (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Cash from Operations of 15234000.0 for Q1 2026, up 129.17% year-over-year from 6647533.55 in Q1 2025, and up 123.65% quarter-over-quarter from 64416000.0 in Q4 2025.
Structure Therapeutics (GPCR) Cash from Operations (2022 - 2026) Analysis & Trends
Structure Therapeutics' Cash from Operations history runs 5 years deep, the most recent figure standing at 15234000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 129.17% year-over-year to 15234000.0; the TTM figure through Mar 2026 stood at 154736000.0 (down 14.8% YoY), while the FY2025 annual figure was 222199000.0, down 90.51% from the prior year.
- Cash from Operations for Q1 2026 stood at 15234000.0, up from 64416000.0 in the prior quarter.
- The five-year high for Cash from Operations was 15234000.0 in Q1 2026, with the low at 64416000.0 in Q4 2025.
- The 5-year median for Cash from Operations is 20557000.0 (2023), against an average of 26424058.82.
- The sharpest annual moves came in 2025 and 2026: Cash from Operations tumbled 158.92% in 2025, then jumped 129.17% in 2026.
- Structure Therapeutics' Cash from Operations stood at 12026000.0 in 2022, then slumped by 80.68% to 21729000.0 in 2023, then slumped by 67.83% to 36467000.0 in 2024, then tumbled by 76.64% to 64416000.0 in 2025, then surged by 123.65% to 15234000.0 in 2026.
- Business Quant data shows GPCR's Cash from Operations at 15234000.0 in Q1 2026, 64416000.0 in Q4 2025, and 50996000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | -120.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -120.12 Mn |
| Jun 30, 2026 | -120.12 Mn |
| Mar 31, 2026 | 15.23 Mn |
| Mar 31, 2026 | 15.23 Mn |
| Dec 31, 2025 | -64.42 Mn |
| Dec 31, 2025 | -64.42 Mn |
| Sep 30, 2025 | -51.00 Mn |
| Sep 30, 2025 | -51.00 Mn |
| Jun 30, 2025 | -54.56 Mn |
| Jun 30, 2025 | -54.56 Mn |
| Mar 31, 2025 | -52.23 Mn |
| Mar 31, 2025 | -52.23 Mn |
| Dec 31, 2024 | -36.47 Mn |
| Dec 31, 2024 | -36.47 Mn |
| Sep 30, 2024 | -19.70 Mn |
| Sep 30, 2024 | -19.70 Mn |
| Jun 30, 2024 | -26.39 Mn |
| Jun 30, 2024 | -26.39 Mn |
| Mar 31, 2024 | -34.08 Mn |
| Mar 31, 2024 | -34.08 Mn |